Finanzen von TuHURA Biosciences Inc (HURA)HURATuHURA Biosciences Inc

Evaluating the bottom line, TuHURA Biosciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -163.84%, provide a clear picture of how effectively HURA converts its operational activities into shareholder value.

In the context of the broader market, HURA competes directly with industry leaders such as FHTX and ARMP. With a market capitalization of $102.61M, it holds a significant position in the sector. When comparing efficiency, HURA's gross margin of N/A stands against FHTX's 100.00% and ARMP's 100.00%. Such benchmarking helps identify whether TuHURA Biosciences Inc is trading at a premium or discount relative to its financial performance.

The financial performance shows a troubling trend with consistent net losses, including a loss of $7.5 million in Q1 2026 and a gross profit of $0 in several quarters, indicating challenges in generating revenue.